Antigen News and Research

RSS

Study shows the QuickNavi-COVID19 Ag test has a high diagnostic performance for SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in nasopharyngeal samples

Researchers evaluated the diagnostic performance of a COVID-19 antigen test during the recent surge caused by the SARS-CoV-2 Omicron variant.

23 May 2022

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Resarchers discuss the ability of shark-derived antibodies to protect against multiple variants of SARS-CoV-2.

23 May 2022

Women who are pregnant or nursing should receive a COVID booster vaccination

In a recent study posted to the medRxiv* preprint server, researchers evaluated the impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) booster vaccination in nursing and pregnant women.

23 May 2022

Researchers discover how one type of T cell creates functionally distinct, but genetically identical daughter cells

Scientists at St. Jude Children's Research Hospital have solved an immunology puzzle. A CD8+ T cell can have two functionally distinct daughter cells after it divides, despite the cells being genetically identical.

20 May 2022

Important methodology for targeting conserved epitopes of SARS-CoV-2 and an immune-focused approach in pan-sarbeco and universal CoV vaccine design

A new study has focused on designing immunogens associated with the conserved region of the spike protein of SARS-CoV-2.

20 May 2022

High-tech’s business model hasn’t worked for the cue covid test

"I've got this," coos Gal Gadot in Cue Health's Super Bowl TV commercial. Cue hired the "Wonder Woman" actress to be the voice of the company's new high-tech covid-19 testing device.

20 May 2022

Identification of long COVID patients through machine learning

Researchers developed a machine learning approach to identify patients with long coronavirus disease.

20 May 2022

Downregulation of MHC-I surface expression by SARS-CoV-2 accessory proteins

Researchers analyze the mechanisms by which two SARS-CoV-2 accessory proteins, ORF3a and ORF7a, can downregulate the expression of MHC-I.

19 May 2022

SARS-CoV-2 Omicron found to be more immune evasive than other variants among mild COVID-19 convalescent patients

Researchers evaluated the humoral and T lymphocyte immune responses against SARS-CoV-2 variants of concern among mild COVID-19 convalescent patients in South Australia.

19 May 2022

Incidence of arterial and venous thromboembolism and death in COVID-19 patients

Researchers estimated the incidence of arterial or venous thrombosis in patients with coronavirus disease 2019.

19 May 2022

In-depth characterization of the BA.2 versus BA.1 variant

In a recent study published in the journal Nature, researchers evaluated the pathogenicity and infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 variant in hamsters and mice.

19 May 2022

Standard blood cancer test holds clear clues of rare IgD multiple myeloma

A test for the common blood cancer multiple myeloma also holds clear clues that the patient has one of the most uncommon and deadly forms of this cancer, investigators say.

19 May 2022

Recombinant protein vaccine stands up to SARS-CoV-2 variants

A study by researchers in Texas describes a mouse model in which a subunit vaccine with alum-CpG adjuvant was tested for its ability to induce a broadly neutralizing antibody response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 May 2022

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

In a new study, researchers evaluated the BNT162b2 coronavirus disease 2019 mRNA vaccine (antigen)-specific immune response among myeloid dysplastic syndrome and chronic lymphocytic leukemia patients.

18 May 2022

How better ventilation can help ‘covid-proof’ your home

For two years, you beat the odds. You masked, kept your distance, got your shots.

18 May 2022

3rd dose of COVID mRNA vaccine expands memory and capacity of immune system to combat Omicron

Researchers from the United States have now found that the immune recall induced by a two-dose primary series of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination after an initial natural infection highly improves the longevity of the antibodies as well as induces an enhanced breadth of protection across the SARS-CoV-2 variants.

17 May 2022